Guangdong Hybribio Biotech Co.,Ltd.

Equities

300639

CNE100002N51

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-06-13 pm EDT			5-day change	1st Jan Change
5.03 ^CNY	-0.98%		-1.95%	-46.15%

May. 21	Hybribio Biotech Gets Patent for Spinal Muscular Atrophy Gene Kit	MT
May. 16	Hybribio Biotech Unit Gets Nod to Market Deafness Gene Detection Kit in China	MT

Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on February 6, 2024.

May 07, 2024 at 05:58 am EDT

From April 1, 2024 to May 7, 2024, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 4,445,000 shares, representing 1.51% for CNY 30.1 million under the buyback announced on February 6, 2024.

Latest news about Guangdong Hybribio Biotech Co.,Ltd.

Hybribio Biotech Gets Patent for Spinal Muscular Atrophy Gene Kit	May. 20	MT
Hybribio Biotech Unit Gets Nod to Market Deafness Gene Detection Kit in China	May. 16	MT
Guangdong Hybribio Biotech Co.,Ltd. Approves Cash Dividend for the Year 2023	May. 15	CI
Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on February 6, 2024.	May. 07	CI
Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback announced on February 6, 2024, has closed with 4,445,000 shares, representing 1.51% for CNY 30.1 million.	May. 06	CI
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Guangdong Hybribio Biotech Co.,Ltd. Proposes Final Dividend for the Year 2023	Apr. 23	CI
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 23	CI
Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on February 6, 2024.	Apr. 01	CI
Guangdong Hybribio Biotech, Subsidiary Get Patent from Brazil for Isolation Method	Mar. 22	MT
Hybribio Biotech's Unit Secures Registration Certificate for Nucleic Acid Analysis System	Feb. 23	MT
Guangdong Hybribio Biotech Co.,Ltd. announces an Equity Buyback for CNY 60 million worth of its shares.	Feb. 05	CI
Guangdong Hybribio Biotech Co.,Ltd. authorizes a Buyback Plan.	Feb. 04	CI
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Two Guangdong Hybribio Biotech Units Get Licenses from Drug Regulator	23-09-04	MT
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Guangdong Hybribio Biotech Registers Gene Testing Kit	23-08-18	MT
Hybribio Showcases Cutting-Edge Cervical Cancer HPV Diagnostic Solutions At ADLM 2023	23-07-31	CI
Hybribio Biotech Appoints Chief Medical Officer	23-06-27	MT
Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on October 26, 2022.	23-05-24	CI
Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback announced on October 26, 2022 has closed with 5,937,000 shares, representing 0.91% for CNY 100 million.	23-05-22	CI
Guangdong Hybribio Biotech Co.,Ltd. Announces Cash Dividend on A Shares for Year 2022, Payable on May 22, 2023	23-05-12	CI
Guangdong Hybribio Biotech Co.,Ltd. Approves Cash Dividend for 2022	23-05-08	CI
Hybribio Biotech Patents HPV Gel in Indonesia	23-05-04	MT
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI

Chart Guangdong Hybribio Biotech Co.,Ltd.

Duration

Period

Chart Guangdong Hybribio Biotech Co.,Ltd.

More charts

Company Profile

Guangdong Hybribio Biotech Co Ltd is a company mainly engaged in production and sales of vitro diagnostic reagents. The Company operates two segments. The In Vitro Diagnostic Reagents and Supporting Equipment segment operates the research, development and production of nucleic acid detection reagents and supporting equipment, such as cervical cancer detection series products, deafness susceptibility gene detection series products and reproductive health management series products. The products are used in hospital clinical testing, large-scale population screening and other areas. The Medical Testing Service segment is involved in providing medical testing services for medical institutions, and the testing programs cover genetic metabolic diseases, infectious diseases, molecular pathological testing and tumor examinations.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-14 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.03

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
GUANGDONG HYBRIBIO BIOTECH CO.,LTD.	-46.15%	445M
BIOMÉRIEUX	-10.54%	11.48B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-9.80%	7.64B
DIASORIN S.P.A.	+3.24%	5.58B
LANTHEUS HOLDINGS, INC.	+27.84%	5.49B
AUTOBIO DIAGNOSTICS CO., LTD.	-15.47%	3.86B
ANDON HEALTH CO., LTD.	+8.47%	2.61B
10X GENOMICS, INC.	-63.81%	2.42B
VITROLIFE AB	-12.33%	2.27B
MYRIAD GENETICS, INC.	+21.21%	2.1B

Diagnostic & Testing Substances